American Society of Hirudotherapy

Transcriptomic profiling and the first spatial expression analysis of candidate genes in the salivary gland of the East Asian medicinal leech, Hirudo nipponia

Kim JH, Lee CJ, Yu YS, Aryal YP, Kim S, Suh JY, Kim JY, Min SH, Cha IT, Lee HY, Shin SY, Cho SJ (2023) · Developmental and Comparative Immunology

Preclinical / molecular study: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.

Study Profile

Model / material
tissue-specific transcriptomic profiling of Hirudo nipponia salivary gland, teeth, and general head region using de novo transcriptome assembly; first spatial expression analysis using in-situ hybridization (Chungbuk National University, Republic of Korea, with Harvard MCZ and Korean institutions)
Method
De novo transcriptome assembly with tissue-specific comparison; in-situ hybridization of candidate genes in H. nipponia salivary gland
Main result
Identified Hni-Antistasin, Hni-Ghilanten, Hni-Bdellin, Hni-Hirudin as anti-coagulant factors; novel Hni-GLIPR1 immune-related gene; first visualization of salivary-gland-specific gene expression sites via in-situ hybridization; expanded sialotranscriptome knowledge for H. nipponia

Key Findings

  • First spatial transcriptomic analysis of an East Asian medicinal-leech salivary gland
  • Tissue-specific anti-coagulant gene cohort identified (Hni-Antistasin, Hni-Ghilanten, Hni-Bdellin, Hni-Hirudin)
  • Novel immune-related Hni-GLIPR1 gene identified
  • In-situ hybridization spatial validation provides cellular-resolution gene localization
  • Complements Lu 2018 H. nipponia sialotranscriptome and Shi 2023 recombinant hirudin work

Limitations

  • Transcriptomic + ISH only — no protein-level validation
  • Limited sample size (small number of biological replicates)
  • Cross-species comparison only with H. medicinalis (not H. manillensis or Whitmania)
  • No clinical or therapeutic translation
  • Hirudo nipponia is not the K040187 device leech

Clinical Implications

Kim 2023 advances the foundational pharmacology of Hirudo nipponia and provides a methodological template for spatial sialotranscriptomics across leech species. For ASH's scientific reference, the study complements existing H. nipponia entries (Lu 2018, Shi 2023) and supports the broader claim that Asian medicinal-leech species harbor anti-coagulant and immune-modulating bioactives distinct from H. medicinalis. No US K040187 clinical-practice implications.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.